factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fact | preserve | 468-472 | 468-472 | T36 | with | PROCESS_OF | 468 | 472 | preserve | 492-500 | 492-500 | T33 | stenosis | PathologicFunction | 492 | 500 | preserve | 459-467 | 459-467 | T30 | patients | PatientOrDisabledGroup | 459 | 467 | A6 | However, the risk-benefit ratio is low in patients with tight asymptomatic stenosis and moderate symptomatic stenosis. | 411-541 | 411 | 541 | However, the risk-benefit ratio is low in @OBJECT$ @PREDICAT$ tight asymptomatic @SUBJECT$ and moderate symptomatic stenosis. |
Fact | preserve | 566-570 | 566-570 | T43 | with | PROCESS_OF | 566 | 570 | preserve | 571-587 | 579-587 | T40 | carotid stenosis | DiseaseOrSyndrome | 571 | 587 | preserve | 557-565 | 557-565 | T39 | patients | PatientOrDisabledGroup | 557 | 565 | A7 | Most stroke in patients with carotid stenosis is believed to be embolic. | 542-620 | 542 | 620 | Most stroke in @OBJECT$ @PREDICAT$ @SUBJECT$ is believed to be embolic. |
Fact | preserve | 554-556 | 554-556 | T42 | in | PROCESS_OF | 554 | 556 | preserve | 547-553 | 547-553 | T38 | stroke | DiseaseOrSyndrome | 547 | 553 | preserve | 557-565 | 557-565 | T39 | patients | PatientOrDisabledGroup | 557 | 565 | A8 | Most stroke in patients with carotid stenosis is believed to be embolic. | 542-620 | 542 | 620 | Most @SUBJECT$ @PREDICAT$ @OBJECT$ with carotid stenosis is believed to be embolic. |
Fact | preserve | 2428-2432 | 2428-2432 | T147 | with | PROCESS_OF | 2,428 | 2,432 | preserve | 2433-2462 | 2454-2462 | T136 | carotid artery stenosis | DiseaseOrSyndrome | 2,433 | 2,462 | preserve | 2419-2427 | 2419-2427 | T135 | patients | PatientOrDisabledGroup | 2,419 | 2,427 | A10 | CONCLUSIONS: Asymptomatic embolization in patients with carotid artery stenosis correlates with known markers of increased stroke risk and is an independent predictor of future stroke risk in patients with both symptomatic and asymptomatic carotid stenosis. | 2377-2652 | 2,377 | 2,652 | CONCLUSIONS: Asymptomatic embolization in @OBJECT$ @PREDICAT$ @SUBJECT$ correlates with known markers of increased stroke risk and is an independent predictor of future stroke risk in patients with both symptomatic and asymptomatic carotid stenosis. |
Probable | preserve | 376-383 | 376-383 | T26 | reduced | PREVENTS | 376 | 383 | preserve | 387-409 | 395-409 | T25 | carotid endarterectomy | TherapeuticOrPreventiveProcedure | 387 | 409 | preserve | 349-355 | 349-355 | T24 | stroke | DiseaseOrSyndrome | 349 | 355 | A13 | This is associated with an increased risk of stroke, which can be reduced by carotid endarterectomy. | 304-410 | 304 | 410 | This is associated with an increased risk of @OBJECT$ , which can be @PREDICAT$ by @SUBJECT$ . |
Fact | preserve | 468-472 | 468-472 | T36 | with | PROCESS_OF | 468 | 472 | preserve | 532-540 | 532-540 | T35 | stenosis | PathologicFunction | 532 | 540 | preserve | 459-467 | 459-467 | T30 | patients | PatientOrDisabledGroup | 459 | 467 | A15 | However, the risk-benefit ratio is low in patients with tight asymptomatic stenosis and moderate symptomatic stenosis. | 411-541 | 411 | 541 | However, the risk-benefit ratio is low in @OBJECT$ @PREDICAT$ tight asymptomatic stenosis and moderate symptomatic @SUBJECT$ . |
Fact | preserve | 2742-2749 | 2742-2749 | T154 | benefit | TREATS | 2,742 | 2,749 | preserve | 2755-2777 | 2763-2777 | T153 | carotid endarterectomy | TherapeuticOrPreventiveProcedure | 2,755 | 2,777 | preserve | 2711-2719 | 2711-2719 | T152 | patients | PatientOrDisabledGroup | 2,711 | 2,719 | A16 | It may allow identification of a high-risk group of patients who will particularly benefit from carotid endarterectomy. | 2653-2778 | 2,653 | 2,778 | It may allow identification of a high-risk group of @OBJECT$ who will particularly @PREDICAT$ from @SUBJECT$ . |
Fact | preserve | 1511-1515 | 1511-1515 | T96 | with | PROCESS_OF | 1,511 | 1,515 | preserve | 1522-1535 | 1529-1535 | T90 | folate intake | Finding | 1,522 | 1,535 | preserve | 1505-1510 | 1505-1510 | T88 | women | PopulationGroup | 1,505 | 1,510 | A2 | The risk of breast cancer associated with alcohol intake was strongest among women with total folate intake of less than 300 microg/d (for alcohol intake > or =15 g/d vs <15 g/d, multivariate RR, 1.32; 95% CI, 1.15-1.50). | 1422-1662 | 1,422 | 1,662 | The risk of breast cancer associated with alcohol intake was strongest among @OBJECT$ @PREDICAT$ total @SUBJECT$ of less than 300 microg/d (for alcohol intake > or =15 g/d vs <15 g/d, multivariate RR, 1.32; 95% CI, 1.15-1.50). |
Fact | preserve | 1499-1504 | 1499-1504 | T95 | among | PROCESS_OF | 1,499 | 1,504 | preserve | 1464-1484 | 1478-1484 | T86 | alcohol intake | IndividualBehavior | 1,464 | 1,484 | preserve | 1505-1510 | 1505-1510 | T88 | women | PopulationGroup | 1,505 | 1,510 | A3 | The risk of breast cancer associated with alcohol intake was strongest among women with total folate intake of less than 300 microg/d (for alcohol intake > or =15 g/d vs <15 g/d, multivariate RR, 1.32; 95% CI, 1.15-1.50). | 1422-1662 | 1,422 | 1,662 | The risk of breast cancer associated with @SUBJECT$ was strongest @PREDICAT$ @OBJECT$ with total folate intake of less than 300 microg/d (for alcohol intake > or =15 g/d vs <15 g/d, multivariate RR, 1.32; 95% CI, 1.15-1.50). |
Fact | preserve | 377-382 | 377-382 | T24 | among | PROCESS_OF | 377 | 382 | preserve | 340-353 | 347-353 | T19 | folate intake | Finding | 340 | 353 | preserve | 383-388 | 383-388 | T22 | women | PopulationGroup | 383 | 388 | A4 | OBJECTIVES: To assess the association between folate intake and risk of breast cancer and whether higher folate intake may reduce excess risk among women who consume alcohol. | 229-415 | 229 | 415 | OBJECTIVES: To assess the association between folate intake and risk of breast cancer and whether higher @SUBJECT$ may reduce excess risk @PREDICAT$ @OBJECT$ who consume alcohol. |
Fact | preserve | 195-199 | 195-199 | T13 | with | PROCESS_OF | 195 | 199 | preserve | 208-227 | 216-227 | T12 | alcohol consumption | IndividualBehavior | 208 | 227 | preserve | 189-194 | 189-194 | T10 | women | PopulationGroup | 189 | 194 | A5 | CONTEXT: Folate is involved in DNA synthesis and methylation and may reduce breast cancer risk, particularly among women with greater alcohol consumption. | 68-228 | 68 | 228 | CONTEXT: Folate is involved in DNA synthesis and methylation and may reduce breast cancer risk, particularly among @OBJECT$ @PREDICAT$ greater @SUBJECT$ . |
Counterfact | preserve | 863-867 | 863-867 | T57 | risk | PREDISPOSES | 863 | 867 | preserve | 817-830 | 824-830 | T52 | folate intake | Finding | 817 | 830 | preserve | 871-884 | 878-884 | T56 | breast cancer | NeoplasticProcess | 871 | 884 | A6 | Total folate intake was not associated with overall risk of breast cancer. | 811-885 | 811 | 885 | Total @SUBJECT$ was not associated with overall @PREDICAT$ of @OBJECT$ . |
Fact | preserve | 1842-1845 | 1842-1845 | T105 | for | TREATS | 1,842 | 1,845 | preserve | 1813-1825 | 1813-1825 | T101 | intervention | HealthCareActivity | 1,813 | 1,825 | preserve | 1851-1858 | 1851-1858 | T102 | patient | PatientOrDisabledGroup | 1,851 | 1,858 | A3 | For patients following a transient ischaemic attack, the results from this simulation and limited cost information suggest that carotid endarterectomy is unlikely to be a cost-effective intervention in the UK for many patient groups despite a reduction in the risk of stroke. | 1615-1908 | 1,615 | 1,908 | For patients following a transient ischaemic attack, the results from this simulation and limited cost information suggest that carotid endarterectomy is unlikely to be a cost-effective @SUBJECT$ in the UK @PREDICAT$ many @OBJECT$ groups despite a reduction in the risk of stroke. |
Fact | preserve | 950-958 | 950-958 | T53 | compared | compared_with | 950 | 958 | preserve | 931-938 | 931-938 | T48 | surgery | TherapeuticOrPreventiveProcedure | 931 | 938 | preserve | 972-981 | 972-981 | T52 | treatment | TherapeuticOrPreventiveProcedure | 972 | 981 | A4 | RESULTS: The baseline scenario of a 65-year-old male patient with the model factors set at an intermediate level showed a benefit for surgery of 3 QALMs compared with medical treatment alone. | 785-988 | 785 | 988 | RESULTS: The baseline scenario of a 65-year-old male patient with the model factors set at an intermediate level showed a benefit for @SUBJECT$ of 3 QALMs @PREDICAT$ with medical @OBJECT$ alone. |
Fact | preserve | 1168-1177 | 1168-1177 | T68 | treatment | TREATS | 1,168 | 1,177 | preserve | 1066-1085 | 1078-1085 | T62 | combination therapy | TherapeuticOrPreventiveProcedure | 1,066 | 1,085 | preserve | 1155-1167 | 1155-1167 | T66 | hypertension | DiseaseOrSyndrome | 1,155 | 1,167 | A1 | AT1 receptor antagonists in both mono-therapy and combination therapy with diuretics/Ca antagonists are very useful and safe in the hypertension treatment. | 1010-1178 | 1,010 | 1,178 | AT1 receptor antagonists in both mono-therapy and @SUBJECT$ with diuretics/Ca antagonists are very useful and safe in the @OBJECT$ @PREDICAT$ . |
Fact | preserve | 355-357 | 355-357 | T27 | in | TREATS | 355 | 357 | preserve | 333-354 | 345-354 | T19 | candesartan cilexetil | OrganicChemical | 333 | 354 | preserve | 378-400 | 388-400 | T21 | essential hypertension | DiseaseOrSyndrome | 378 | 400 | A2 | In Japan, the efficacy and safty of losartan and candesartan cilexetil in patients with essential hypertension have been evaluated by the double-blind, parallel group-comparison study using enelaprol maleate as control drug. | 278-520 | 278 | 520 | In Japan, the efficacy and safty of losartan and @SUBJECT$ @PREDICAT$ patients with @OBJECT$ have been evaluated by the double-blind, parallel group-comparison study using enelaprol maleate as control drug. |
Fact | preserve | 355-357 | 355-357 | T27 | in | TREATS | 355 | 357 | preserve | 320-328 | 320-328 | T18 | losartan | OrganicChemical | 320 | 328 | preserve | 378-400 | 388-400 | T21 | essential hypertension | DiseaseOrSyndrome | 378 | 400 | A3 | In Japan, the efficacy and safty of losartan and candesartan cilexetil in patients with essential hypertension have been evaluated by the double-blind, parallel group-comparison study using enelaprol maleate as control drug. | 278-520 | 278 | 520 | In Japan, the efficacy and safty of @SUBJECT$ and candesartan cilexetil @PREDICAT$ patients with @OBJECT$ have been evaluated by the double-blind, parallel group-comparison study using enelaprol maleate as control drug. |
Fact | preserve | 250-253 | 250-253 | T15 | for | TREATS | 250 | 253 | preserve | 136-178 | 167-178 | T8 | angiotensin II type 1-receptor antagonists | PharmacologicSubstance | 136 | 178 | preserve | 254-276 | 264-276 | T14 | essential hypertension | DiseaseOrSyndrome | 254 | 276 | A4 | Nonpeptide angiotensin II type 1-receptor antagonists, AT1 receptor antagonists, are newly developed and useful drugs for essential hypertension. | 125-277 | 125 | 277 | Nonpeptide @SUBJECT$ , AT1 receptor antagonists, are newly developed and useful drugs @PREDICAT$ @OBJECT$ . |
Fact | preserve | 712-714 | 712-714 | T44 | in | PROCESS_OF | 712 | 714 | preserve | 685-690 | 685-690 | T40 | cough | SignOrSymptom | 685 | 690 | preserve | 724-732 | 724-732 | T42 | patients | PatientOrDisabledGroup | 724 | 732 | A5 | Both trials revealed that these drugs showed a hypotensive effect comparable to that of enalapril with a high safety since the adverse drug reaction of cough was recognized in very few patients. | 521-733 | 521 | 733 | Both trials revealed that these drugs showed a hypotensive effect comparable to that of enalapril with a high safety since the adverse drug reaction of @SUBJECT$ was recognized @PREDICAT$ very few @OBJECT$ . |
Fact | preserve | 367-371 | 367-371 | T29 | with | PROCESS_OF | 367 | 371 | preserve | 378-400 | 388-400 | T21 | essential hypertension | DiseaseOrSyndrome | 378 | 400 | preserve | 358-366 | 358-366 | T20 | patients | PatientOrDisabledGroup | 358 | 366 | A6 | In Japan, the efficacy and safty of losartan and candesartan cilexetil in patients with essential hypertension have been evaluated by the double-blind, parallel group-comparison study using enelaprol maleate as control drug. | 278-520 | 278 | 520 | In Japan, the efficacy and safty of losartan and candesartan cilexetil in @OBJECT$ @PREDICAT$ @SUBJECT$ have been evaluated by the double-blind, parallel group-comparison study using enelaprol maleate as control drug. |
Fact | preserve | 355-357 | 355-357 | T27 | in | TREATS | 355 | 357 | preserve | 320-328 | 320-328 | T18 | losartan | OrganicChemical | 320 | 328 | preserve | 358-366 | 358-366 | T20 | patients | PatientOrDisabledGroup | 358 | 366 | A7 | In Japan, the efficacy and safty of losartan and candesartan cilexetil in patients with essential hypertension have been evaluated by the double-blind, parallel group-comparison study using enelaprol maleate as control drug. | 278-520 | 278 | 520 | In Japan, the efficacy and safty of @SUBJECT$ and candesartan cilexetil @PREDICAT$ @OBJECT$ with essential hypertension have been evaluated by the double-blind, parallel group-comparison study using enelaprol maleate as control drug. |
Fact | preserve | 96-99 | 96-99 | T7 | for | TREATS | 96 | 99 | preserve | 54-94 | 84-94 | T4 | angiotensin II receptor antagonist | PharmacologicSubstance | 54 | 94 | preserve | 100-122 | 110-122 | T5 | essential hypertension | DiseaseOrSyndrome | 100 | 122 | A8 | [The usefulness of a new class antihypertensive drug, angiotensin II receptor antagonist, for essential hypertension]. | 0-124 | 0 | 124 | [The usefulness of a new class antihypertensive drug, @SUBJECT$ , @PREDICAT$ @OBJECT$ ]. |
Fact | preserve | 775-777 | 775-777 | T51 | in | PROCESS_OF | 775 | 777 | preserve | 744-758 | 750-758 | T45 | blood pressure | Finding | 744 | 758 | preserve | 789-796 | 789-796 | T46 | patient | PatientOrDisabledGroup | 789 | 796 | A9 | Since the blood pressure normalizes only in the patient of about 50%, it is often required to add low-dose hydrochlorothiazide or calcium antagonist. | 734-896 | 734 | 896 | Since the @SUBJECT$ normalizes only @PREDICAT$ the @OBJECT$ of about 50%, it is often required to add low-dose hydrochlorothiazide or calcium antagonist. |
Fact | preserve | 31-94 | 84-94 | T6 | antihypertensive drug, angiotensin II receptor antagonist | ISA | 31 | 94 | preserve | 54-94 | 84-94 | T4 | angiotensin II receptor antagonist | PharmacologicSubstance | 54 | 94 | preserve | 31-52 | 48-52 | T3 | antihypertensive drug | PharmacologicSubstance | 31 | 52 | A10 | [The usefulness of a new class antihypertensive drug, angiotensin II receptor antagonist, for essential hypertension]. | 0-124 | 0 | 124 | [The usefulness of a new class @OBJECT$ @PREDICAT$ @SUBJECT$ , for essential hypertension]. |
Fact | preserve | 250-253 | 250-253 | T15 | for | TREATS | 250 | 253 | preserve | 244-249 | 244-249 | T13 | drugs | PharmacologicSubstance | 244 | 249 | preserve | 254-276 | 264-276 | T14 | essential hypertension | DiseaseOrSyndrome | 254 | 276 | A12 | Nonpeptide angiotensin II type 1-receptor antagonists, AT1 receptor antagonists, are newly developed and useful drugs for essential hypertension. | 125-277 | 125 | 277 | Nonpeptide angiotensin II type 1-receptor antagonists, AT1 receptor antagonists, are newly developed and useful @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 355-357 | 355-357 | T27 | in | TREATS | 355 | 357 | preserve | 333-354 | 345-354 | T19 | candesartan cilexetil | OrganicChemical | 333 | 354 | preserve | 358-366 | 358-366 | T20 | patients | PatientOrDisabledGroup | 358 | 366 | A14 | In Japan, the efficacy and safty of losartan and candesartan cilexetil in patients with essential hypertension have been evaluated by the double-blind, parallel group-comparison study using enelaprol maleate as control drug. | 278-520 | 278 | 520 | In Japan, the efficacy and safty of losartan and @SUBJECT$ @PREDICAT$ @OBJECT$ with essential hypertension have been evaluated by the double-blind, parallel group-comparison study using enelaprol maleate as control drug. |
Fact | preserve | 1607-1656 | 1634-1638 | T107 | angioplasty is superior to t-PA for the treatment | ISA | 1,607 | 1,656 | preserve | 1634-1638 | 1634-1638 | T100 | t-PA | AminoAcidPeptideOrProtein | 1,634 | 1,638 | preserve | 1647-1656 | 1647-1656 | T101 | treatment | TherapeuticOrPreventiveProcedure | 1,647 | 1,656 | A1 | CONCLUSIONS: In centers with an experienced and readily available interventional team, primary angioplasty is superior to t-PA for the treatment of anterior AMI. | 1499-1673 | 1,499 | 1,673 | CONCLUSIONS: In centers with an experienced and readily available interventional team, primary @PREDICAT$ @SUBJECT$ for the @OBJECT$ of anterior AMI. |
Fact | preserve | 1631-1633 | 1631-1633 | T105 | to | compared_with | 1,631 | 1,633 | preserve | 1607-1618 | 1607-1618 | T98 | angioplasty | TherapeuticOrPreventiveProcedure | 1,607 | 1,618 | preserve | 1634-1638 | 1634-1638 | T100 | t-PA | AminoAcidPeptideOrProtein | 1,634 | 1,638 | A2 | CONCLUSIONS: In centers with an experienced and readily available interventional team, primary angioplasty is superior to t-PA for the treatment of anterior AMI. | 1499-1673 | 1,499 | 1,673 | CONCLUSIONS: In centers with an experienced and readily available interventional team, primary @SUBJECT$ is superior @PREDICAT$ @OBJECT$ for the treatment of anterior AMI. |
Fact | preserve | 1631-1633 | 1631-1633 | T106 | to | higher_than | 1,631 | 1,633 | preserve | 1607-1618 | 1607-1618 | T98 | angioplasty | TherapeuticOrPreventiveProcedure | 1,607 | 1,618 | preserve | 1634-1638 | 1634-1638 | T100 | t-PA | AminoAcidPeptideOrProtein | 1,634 | 1,638 | A3 | CONCLUSIONS: In centers with an experienced and readily available interventional team, primary angioplasty is superior to t-PA for the treatment of anterior AMI. | 1499-1673 | 1,499 | 1,673 | CONCLUSIONS: In centers with an experienced and readily available interventional team, primary @SUBJECT$ is superior @PREDICAT$ @OBJECT$ for the treatment of anterior AMI. |
Fact | preserve | 1607-1656 | 1634-1638 | T107 | angioplasty is superior to t-PA for the treatment | ISA | 1,607 | 1,656 | preserve | 1607-1618 | 1607-1618 | T98 | angioplasty | TherapeuticOrPreventiveProcedure | 1,607 | 1,618 | preserve | 1647-1656 | 1647-1656 | T101 | treatment | TherapeuticOrPreventiveProcedure | 1,647 | 1,656 | A4 | CONCLUSIONS: In centers with an experienced and readily available interventional team, primary angioplasty is superior to t-PA for the treatment of anterior AMI. | 1499-1673 | 1,499 | 1,673 | CONCLUSIONS: In centers with an experienced and readily available interventional team, primary @SUBJECT$ @PREDICAT$ @OBJECT$ of anterior AMI. |
Uncommitted | preserve | 49-51 | 49-51 | T5 | in | TREATS | 49 | 51 | preserve | 8-19 | 8-19 | T1 | angioplasty | TherapeuticOrPreventiveProcedure | 8 | 19 | preserve | 52-88 | 78-88 | T4 | anterior myocardial infarction | DiseaseOrSyndrome | 52 | 88 | A5 | Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. | 0-89 | 0 | 89 | Primary @SUBJECT$ versus systemic thrombolysis @PREDICAT$ @OBJECT$ . |
Fact | preserve | 976-983 | 976-983 | T78 | treated | TREATS | 976 | 983 | preserve | 987-998 | 987-998 | T61 | angioplasty | TherapeuticOrPreventiveProcedure | 987 | 998 | preserve | 967-975 | 967-975 | T60 | patients | PatientOrDisabledGroup | 967 | 975 | A7 | During hospitalization, patients treated by angioplasty had a lower frequency of postinfarction angina or positive stress test (11.9% vs. | 943-1086 | 943 | 1,086 | During hospitalization, @OBJECT$ @PREDICAT$ by @SUBJECT$ had a lower frequency of postinfarction angina or positive stress test (11.9% vs. |
Fact | preserve | 1647-1656 | 1647-1656 | T109 | treatment | TREATS | 1,647 | 1,656 | preserve | 1607-1618 | 1607-1618 | T98 | angioplasty | TherapeuticOrPreventiveProcedure | 1,607 | 1,618 | preserve | 1669-1672 | 1669-1672 | T103 | AMI | DiseaseOrSyndrome | 1,669 | 1,672 | A8 | CONCLUSIONS: In centers with an experienced and readily available interventional team, primary angioplasty is superior to t-PA for the treatment of anterior AMI. | 1499-1673 | 1,499 | 1,673 | CONCLUSIONS: In centers with an experienced and readily available interventional team, primary @SUBJECT$ is superior to t-PA for the @PREDICAT$ of anterior @OBJECT$ . |
Fact | preserve | 401-404 | 401-404 | T26 | for | TREATS | 401 | 404 | preserve | 391-400 | 391-400 | T24 | treatment | TherapeuticOrPreventiveProcedure | 391 | 400 | preserve | 405-408 | 405-408 | T25 | AMI | DiseaseOrSyndrome | 405 | 408 | A9 | BACKGROUND: Controversy still exists about the relative benefit of primary angioplasty over thrombolysis as treatment for AMI. | 276-409 | 276 | 409 | BACKGROUND: Controversy still exists about the relative benefit of primary angioplasty over thrombolysis as @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1271-1278 | 1271-1278 | T80 | treated | TREATS | 1,271 | 1,278 | preserve | 1282-1286 | 1282-1286 | T76 | t-PA | AminoAcidPeptideOrProtein | 1,282 | 1,286 | preserve | 1256-1264 | 1256-1264 | T75 | patients | PatientOrDisabledGroup | 1,256 | 1,264 | A10 | 47.7%, p < 0.001) than did patients treated by t-PA. | 1229-1287 | 1,229 | 1,287 | 47.7%, p < 0.001) than did @OBJECT$ @PREDICAT$ by @SUBJECT$ . |
Fact | preserve | 251-255 | 251-255 | T18 | with | PROCESS_OF | 251 | 255 | preserve | 271-274 | 271-274 | T16 | AMI | DiseaseOrSyndrome | 271 | 274 | preserve | 242-250 | 242-250 | T14 | patients | PatientOrDisabledGroup | 242 | 250 | A11 | OBJECTIVES: This study compares the efficacy of primary angioplasty and systemic thrombolysis with t-PA in reducing the in-hospital mortality of patients with anterior AMI. | 90-275 | 90 | 275 | OBJECTIVES: This study compares the efficacy of primary angioplasty and systemic thrombolysis with t-PA in reducing the in-hospital mortality of @OBJECT$ @PREDICAT$ anterior @SUBJECT$ . |
Fact | preserve | 1190-1195 | 1190-1195 | T79 | after | PRECEDES | 1,190 | 1,195 | preserve | 1208-1217 | 1208-1217 | T74 | treatment | TherapeuticOrPreventiveProcedure | 1,208 | 1,217 | preserve | 1166-1183 | 1166-1183 | T72 | revascularization | TherapeuticOrPreventiveProcedure | 1,166 | 1,183 | A14 | 25.2%, p = 0.01) and less frequently underwent percutaneous or surgical revascularization after the initial treatment (22.0% vs. | 1087-1228 | 1,087 | 1,228 | 25.2%, p = 0.01) and less frequently underwent percutaneous or surgical @OBJECT$ @PREDICAT$ the initial @SUBJECT$ (22.0% vs. |
Fact | preserve | 113-121 | 113-121 | T17 | compares | compared_with | 113 | 121 | preserve | 146-157 | 146-157 | T8 | angioplasty | TherapeuticOrPreventiveProcedure | 146 | 157 | preserve | 196-200 | 196-200 | T11 | t-PA | AminoAcidPeptideOrProtein | 196 | 200 | A15 | OBJECTIVES: This study compares the efficacy of primary angioplasty and systemic thrombolysis with t-PA in reducing the in-hospital mortality of patients with anterior AMI. | 90-275 | 90 | 275 | OBJECTIVES: This study @PREDICAT$ the efficacy of primary @SUBJECT$ and systemic thrombolysis with @OBJECT$ in reducing the in-hospital mortality of patients with anterior AMI. |
Fact | preserve | 458-462 | 458-462 | T45 | with | PROCESS_OF | 458 | 462 | preserve | 472-475 | 472-475 | T31 | AMI | DiseaseOrSyndrome | 472 | 475 | preserve | 449-457 | 449-457 | T29 | patients | PatientOrDisabledGroup | 449 | 457 | A16 | METHODS: Two-hundred and twenty patients with anterior AMI were randomly assigned in our institution to primary angioplasty (109 patients) or systemic thrombolysis with accelerated t-PA (111 patients) within the first five hours from the onset of symptoms. | 410-685 | 410 | 685 | METHODS: Two-hundred and twenty @OBJECT$ @PREDICAT$ anterior @SUBJECT$ were randomly assigned in our institution to primary angioplasty (109 patients) or systemic thrombolysis with accelerated t-PA (111 patients) within the first five hours from the onset of symptoms. |
Fact | preserve | 1647-1656 | 1647-1656 | T109 | treatment | TREATS | 1,647 | 1,656 | preserve | 1634-1638 | 1634-1638 | T100 | t-PA | AminoAcidPeptideOrProtein | 1,634 | 1,638 | preserve | 1669-1672 | 1669-1672 | T103 | AMI | DiseaseOrSyndrome | 1,669 | 1,672 | A17 | CONCLUSIONS: In centers with an experienced and readily available interventional team, primary angioplasty is superior to t-PA for the treatment of anterior AMI. | 1499-1673 | 1,499 | 1,673 | CONCLUSIONS: In centers with an experienced and readily available interventional team, primary angioplasty is superior to @SUBJECT$ for the @PREDICAT$ of anterior @OBJECT$ . |
Fact | preserve | 832-849 | 841-849 | T48 | migraine patients | PROCESS_OF | 832 | 849 | preserve | 832-840 | 832-840 | T45 | migraine | DiseaseOrSyndrome | 832 | 840 | preserve | 841-849 | 841-849 | T46 | patients | PatientOrDisabledGroup | 841 | 849 | A1 | We believe that the use of these migraine models will provide even better treatment for migraine patients in the next millennium. | 737-879 | 737 | 879 | We believe that the use of these migraine models will provide even better treatment for @SUBJECT$ @PREDICAT$ @OBJECT$ in the next millennium. |
Fact | preserve | 828-831 | 828-831 | T49 | for | TREATS | 828 | 831 | preserve | 818-827 | 818-827 | T44 | treatment | TherapeuticOrPreventiveProcedure | 818 | 827 | preserve | 832-840 | 832-840 | T45 | migraine | DiseaseOrSyndrome | 832 | 840 | A2 | We believe that the use of these migraine models will provide even better treatment for migraine patients in the next millennium. | 737-879 | 737 | 879 | We believe that the use of these migraine models will provide even better @SUBJECT$ @PREDICAT$ @OBJECT$ patients in the next millennium. |
Fact | preserve | 170-177 | 170-177 | T19 | therapy | TREATS | 170 | 177 | preserve | 202-213 | 202-213 | T12 | sumatriptan | OrganicChemical | 202 | 213 | preserve | 187-195 | 187-195 | T11 | migraine | DiseaseOrSyndrome | 187 | 195 | A4 | The last decade has witnessed a tremendous progress in the acute therapy of migraine, with sumatriptan, belonging to a new class of drugs, now known as 5-HT(1B/1D/1F) receptor agonists, leading the way. | 105-319 | 105 | 319 | The last decade has witnessed a tremendous progress in the acute @PREDICAT$ of @OBJECT$ , with @SUBJECT$ , belonging to a new class of drugs, now known as 5-HT(1B/1D/1F) receptor agonists, leading the way. |
Fact | preserve | 828-831 | 828-831 | T49 | for | TREATS | 828 | 831 | preserve | 818-827 | 818-827 | T44 | treatment | TherapeuticOrPreventiveProcedure | 818 | 827 | preserve | 841-849 | 841-849 | T46 | patients | PatientOrDisabledGroup | 841 | 849 | A6 | We believe that the use of these migraine models will provide even better treatment for migraine patients in the next millennium. | 737-879 | 737 | 879 | We believe that the use of these migraine models will provide even better @SUBJECT$ @PREDICAT$ migraine @OBJECT$ in the next millennium. |
Fact | preserve | 697-709 | 700-709 | T54 | AG treatment | ISA | 697 | 709 | preserve | 697-699 | 697-699 | T52 | AG | OrganicChemical | 697 | 699 | preserve | 700-709 | 700-709 | T53 | treatment | TherapeuticOrPreventiveProcedure | 700 | 709 | A1 | These results may explain why some patients failed therapy after extensive AG treatment. | 615-710 | 615 | 710 | These results may explain why some patients failed therapy after extensive @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 545-557 | 548-557 | T46 | AG treatment | USES | 545 | 557 | preserve | 548-557 | 548-557 | T39 | treatment | TherapeuticOrPreventiveProcedure | 548 | 557 | preserve | 545-547 | 545-547 | T38 | AG | OrganicChemical | 545 | 547 | A3 | While AG is effective in inhibiting aromatase, it was found that aromatase activity in tumors of some breast cancer patients elevated after AG treatment (Miller and O'Neill, Steroids, 50: 245-252, 1987). | 399-614 | 399 | 614 | While AG is effective in inhibiting aromatase, it was found that aromatase activity in tumors of some breast cancer patients elevated after @OBJECT$ @PREDICAT$ @SUBJECT$ (Miller and O'Neill, Steroids, 50: 245-252, 1987). |
Fact | preserve | 741-753 | 744-753 | T69 | AG treatment | USES | 741 | 753 | preserve | 744-753 | 744-753 | T61 | treatment | TherapeuticOrPreventiveProcedure | 744 | 753 | preserve | 741-743 | 741-743 | T60 | AG | OrganicChemical | 741 | 743 | A4 | Recently, we found that AG treatment increased aromatase activity in SK-BR-3, JAR, and HepG2 cell lines in a dose- and incubation time-dependent manner. | 711-875 | 711 | 875 | Recently, we found that @OBJECT$ @PREDICAT$ @SUBJECT$ increased aromatase activity in SK-BR-3, JAR, and HepG2 cell lines in a dose- and incubation time-dependent manner. |
Fact | preserve | 296-350 | 341-350 | T29 | Aminoglutethimide (AG) is an aromatase inhibitor | TREATS | 296 | 350 | preserve | 296-313 | 296-313 | T23 | Aminoglutethimide | OrganicChemical | 296 | 313 | preserve | 384-397 | 391-397 | T26 | breast cancer | NeoplasticProcess | 384 | 397 | A5 | Aminoglutethimide (AG) is an aromatase inhibitor used to treat estrogen-dependent breast cancer. | 296-398 | 296 | 398 | @SUBJECT$ @PREDICAT$ used to treat estrogen-dependent @OBJECT$ . |
Fact | preserve | 1135-1147 | 1138-1147 | T91 | AG treatment | ISA | 1,135 | 1,147 | preserve | 1135-1137 | 1135-1137 | T82 | AG | OrganicChemical | 1,135 | 1,137 | preserve | 1138-1147 | 1138-1147 | T83 | treatment | TherapeuticOrPreventiveProcedure | 1,138 | 1,147 | A6 | AG induction is thought to occur at the transcriptional level because the aromatase mRNA level elevated after AG treatment in SK-BR-3 and HepG2 cells, as demonstrated by reverse transcription-polymerase chain reaction (RT-PCR) analysis, and AG treatment did not increase aromatase activity in aromatase cDNA transfected cell lines (driven by the beta-actin promoter). | 876-1274 | 876 | 1,274 | AG induction is thought to occur at the transcriptional level because the aromatase mRNA level elevated after AG treatment in SK-BR-3 and HepG2 cells, as demonstrated by reverse transcription-polymerase chain reaction (RT-PCR) analysis, and @SUBJECT$ @PREDICAT$ @OBJECT$ did not increase aromatase activity in aromatase cDNA transfected cell lines (driven by the beta-actin promoter). |
Fact | preserve | 545-557 | 548-557 | T42 | AG treatment | ISA | 545 | 557 | preserve | 545-547 | 545-547 | T38 | AG | OrganicChemical | 545 | 547 | preserve | 548-557 | 548-557 | T39 | treatment | TherapeuticOrPreventiveProcedure | 548 | 557 | A8 | While AG is effective in inhibiting aromatase, it was found that aromatase activity in tumors of some breast cancer patients elevated after AG treatment (Miller and O'Neill, Steroids, 50: 245-252, 1987). | 399-614 | 399 | 614 | While AG is effective in inhibiting aromatase, it was found that aromatase activity in tumors of some breast cancer patients elevated after @SUBJECT$ @PREDICAT$ @OBJECT$ (Miller and O'Neill, Steroids, 50: 245-252, 1987). |
Fact | preserve | 681-686 | 681-686 | T56 | after | PRECEDES | 681 | 686 | preserve | 700-709 | 700-709 | T53 | treatment | TherapeuticOrPreventiveProcedure | 700 | 709 | preserve | 673-680 | 673-680 | T50 | therapy | TherapeuticOrPreventiveProcedure | 673 | 680 | A9 | These results may explain why some patients failed therapy after extensive AG treatment. | 615-710 | 615 | 710 | These results may explain why some patients failed @OBJECT$ @PREDICAT$ extensive AG @SUBJECT$ . |
Fact | preserve | 507-529 | 521-529 | T44 | breast cancer patients | PROCESS_OF | 507 | 529 | preserve | 507-520 | 514-520 | T36 | breast cancer | NeoplasticProcess | 507 | 520 | preserve | 521-529 | 521-529 | T37 | patients | PatientOrDisabledGroup | 521 | 529 | A10 | While AG is effective in inhibiting aromatase, it was found that aromatase activity in tumors of some breast cancer patients elevated after AG treatment (Miller and O'Neill, Steroids, 50: 245-252, 1987). | 399-614 | 399 | 614 | While AG is effective in inhibiting aromatase, it was found that aromatase activity in tumors of some @SUBJECT$ @PREDICAT$ @OBJECT$ elevated after AG treatment (Miller and O'Neill, Steroids, 50: 245-252, 1987). |
Fact | preserve | 275-294 | 286-294 | T21 | estrogenic steroids | ISA | 275 | 294 | preserve | 275-285 | 275-285 | T19 | estrogenic | Hormone | 275 | 285 | preserve | 286-294 | 286-294 | T20 | steroids | Steroid | 286 | 294 | A11 | Aromatase, a cytochrome P450, catalyzes three consecutive hydroxylation reactions converting C19 androgens to aromatic C18 estrogenic steroids. | 146-295 | 146 | 295 | Aromatase, a cytochrome P450, catalyzes three consecutive hydroxylation reactions converting C19 androgens to aromatic C18 @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 359-364 | 359-364 | T28 | treat | TREATS | 359 | 364 | preserve | 331-350 | 341-350 | T24 | aromatase inhibitor | PharmacologicSubstance | 331 | 350 | preserve | 384-397 | 391-397 | T26 | breast cancer | NeoplasticProcess | 384 | 397 | A13 | Aminoglutethimide (AG) is an aromatase inhibitor used to treat estrogen-dependent breast cancer. | 296-398 | 296 | 398 | Aminoglutethimide (AG) is an @SUBJECT$ used to @PREDICAT$ estrogen-dependent @OBJECT$ . |
Fact | preserve | 1681-1686 | 1681-1686 | T122 | after | PRECEDES | 1,681 | 1,686 | preserve | 1700-1709 | 1700-1709 | T119 | treatment | TherapeuticOrPreventiveProcedure | 1,700 | 1,709 | preserve | 1673-1680 | 1673-1680 | T116 | therapy | TherapeuticOrPreventiveProcedure | 1,673 | 1,680 | A14 | Our study provides an insight as to why some patients fail therapy after extensive AG treatment. | 1608-1710 | 1,608 | 1,710 | Our study provides an insight as to why some patients fail @OBJECT$ @PREDICAT$ extensive AG @SUBJECT$ . |
Fact | preserve | 1465-1477 | 1468-1477 | T112 | AG induction | USES | 1,465 | 1,477 | preserve | 1468-1477 | 1468-1477 | T106 | induction | TherapeuticOrPreventiveProcedure | 1,468 | 1,477 | preserve | 1465-1467 | 1465-1467 | T105 | AG | OrganicChemical | 1,465 | 1,467 | A15 | Furthermore, since the AG induction was found to be suppressed by SQ 22536, an adenylate cyclase inhibitor, a cAMP-dependent mechanism might be involved. | 1442-1607 | 1,442 | 1,607 | Furthermore, since the @OBJECT$ @PREDICAT$ @SUBJECT$ was found to be suppressed by SQ 22536, an adenylate cyclase inhibitor, a cAMP-dependent mechanism might be involved. |
Fact | preserve | 296-350 | 341-350 | T27 | Aminoglutethimide (AG) is an aromatase inhibitor | ISA | 296 | 350 | preserve | 296-313 | 296-313 | T23 | Aminoglutethimide | OrganicChemical | 296 | 313 | preserve | 331-350 | 341-350 | T24 | aromatase inhibitor | PharmacologicSubstance | 331 | 350 | A16 | Aminoglutethimide (AG) is an aromatase inhibitor used to treat estrogen-dependent breast cancer. | 296-398 | 296 | 398 | @SUBJECT$ @PREDICAT$ @OBJECT$ used to treat estrogen-dependent breast cancer. |
Fact | preserve | 1697-1709 | 1700-1709 | T121 | AG treatment | USES | 1,697 | 1,709 | preserve | 1700-1709 | 1700-1709 | T119 | treatment | TherapeuticOrPreventiveProcedure | 1,700 | 1,709 | preserve | 1697-1699 | 1697-1699 | T118 | AG | OrganicChemical | 1,697 | 1,699 | A17 | Our study provides an insight as to why some patients fail therapy after extensive AG treatment. | 1608-1710 | 1,608 | 1,710 | Our study provides an insight as to why some patients fail therapy after extensive @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1135-1147 | 1138-1147 | T95 | AG treatment | USES | 1,135 | 1,147 | preserve | 1138-1147 | 1138-1147 | T83 | treatment | TherapeuticOrPreventiveProcedure | 1,138 | 1,147 | preserve | 1135-1137 | 1135-1137 | T82 | AG | OrganicChemical | 1,135 | 1,137 | A18 | AG induction is thought to occur at the transcriptional level because the aromatase mRNA level elevated after AG treatment in SK-BR-3 and HepG2 cells, as demonstrated by reverse transcription-polymerase chain reaction (RT-PCR) analysis, and AG treatment did not increase aromatase activity in aromatase cDNA transfected cell lines (driven by the beta-actin promoter). | 876-1274 | 876 | 1,274 | AG induction is thought to occur at the transcriptional level because the aromatase mRNA level elevated after AG treatment in SK-BR-3 and HepG2 cells, as demonstrated by reverse transcription-polymerase chain reaction (RT-PCR) analysis, and @OBJECT$ @PREDICAT$ @SUBJECT$ did not increase aromatase activity in aromatase cDNA transfected cell lines (driven by the beta-actin promoter). |
Fact | preserve | 101-106 | 101-106 | T9 | treat | TREATS | 101 | 106 | preserve | 59-78 | 69-78 | T5 | aromatase inhibitor | PharmacologicSubstance | 59 | 78 | preserve | 107-120 | 114-120 | T6 | breast cancer | NeoplasticProcess | 107 | 120 | A19 | Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women. | 0-145 | 0 | 145 | Induction of aromatase expression by aminoglutethimide, an @SUBJECT$ that is used to @PREDICAT$ @OBJECT$ in postmenopausal women. |
Fact | preserve | 998-1010 | 1001-1010 | T90 | AG treatment | ISA | 998 | 1,010 | preserve | 998-1000 | 998-1000 | T76 | AG | OrganicChemical | 998 | 1,000 | preserve | 1001-1010 | 1001-1010 | T77 | treatment | TherapeuticOrPreventiveProcedure | 1,001 | 1,010 | A21 | AG induction is thought to occur at the transcriptional level because the aromatase mRNA level elevated after AG treatment in SK-BR-3 and HepG2 cells, as demonstrated by reverse transcription-polymerase chain reaction (RT-PCR) analysis, and AG treatment did not increase aromatase activity in aromatase cDNA transfected cell lines (driven by the beta-actin promoter). | 876-1274 | 876 | 1,274 | AG induction is thought to occur at the transcriptional level because the aromatase mRNA level elevated after @SUBJECT$ @PREDICAT$ @OBJECT$ in SK-BR-3 and HepG2 cells, as demonstrated by reverse transcription-polymerase chain reaction (RT-PCR) analysis, and AG treatment did not increase aromatase activity in aromatase cDNA transfected cell lines (driven by the beta-actin promoter). |
Fact | preserve | 741-753 | 744-753 | T68 | AG treatment | ISA | 741 | 753 | preserve | 741-743 | 741-743 | T60 | AG | OrganicChemical | 741 | 743 | preserve | 744-753 | 744-753 | T61 | treatment | TherapeuticOrPreventiveProcedure | 744 | 753 | A22 | Recently, we found that AG treatment increased aromatase activity in SK-BR-3, JAR, and HepG2 cell lines in a dose- and incubation time-dependent manner. | 711-875 | 711 | 875 | Recently, we found that @SUBJECT$ @PREDICAT$ @OBJECT$ increased aromatase activity in SK-BR-3, JAR, and HepG2 cell lines in a dose- and incubation time-dependent manner. |
Fact | preserve | 499-501 | 499-501 | T45 | of | PART_OF | 499 | 501 | preserve | 492-498 | 492-498 | T35 | tumors | NeoplasticProcess | 492 | 498 | preserve | 521-529 | 521-529 | T37 | patients | PatientOrDisabledGroup | 521 | 529 | A23 | While AG is effective in inhibiting aromatase, it was found that aromatase activity in tumors of some breast cancer patients elevated after AG treatment (Miller and O'Neill, Steroids, 50: 245-252, 1987). | 399-614 | 399 | 614 | While AG is effective in inhibiting aromatase, it was found that aromatase activity in @SUBJECT$ @PREDICAT$ some breast cancer @OBJECT$ elevated after AG treatment (Miller and O'Neill, Steroids, 50: 245-252, 1987). |
Fact | preserve | 0-9 | 0-9 | T8 | Induction | STIMULATES | 0 | 9 | preserve | 37-54 | 37-54 | T4 | aminoglutethimide | OrganicChemical | 37 | 54 | preserve | 13-22 | 13-22 | T2 | aromatase | AminoAcidPeptideOrProtein | 13 | 22 | A24 | Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women. | 0-145 | 0 | 145 | @PREDICAT$ of @OBJECT$ expression by @SUBJECT$ , an aromatase inhibitor that is used to treat breast cancer in postmenopausal women. |
Fact | preserve | 998-1010 | 1001-1010 | T94 | AG treatment | USES | 998 | 1,010 | preserve | 1001-1010 | 1001-1010 | T77 | treatment | TherapeuticOrPreventiveProcedure | 1,001 | 1,010 | preserve | 998-1000 | 998-1000 | T76 | AG | OrganicChemical | 998 | 1,000 | A26 | AG induction is thought to occur at the transcriptional level because the aromatase mRNA level elevated after AG treatment in SK-BR-3 and HepG2 cells, as demonstrated by reverse transcription-polymerase chain reaction (RT-PCR) analysis, and AG treatment did not increase aromatase activity in aromatase cDNA transfected cell lines (driven by the beta-actin promoter). | 876-1274 | 876 | 1,274 | AG induction is thought to occur at the transcriptional level because the aromatase mRNA level elevated after @OBJECT$ @PREDICAT$ @SUBJECT$ in SK-BR-3 and HepG2 cells, as demonstrated by reverse transcription-polymerase chain reaction (RT-PCR) analysis, and AG treatment did not increase aromatase activity in aromatase cDNA transfected cell lines (driven by the beta-actin promoter). |
Fact | preserve | 1697-1709 | 1700-1709 | T124 | AG treatment | PRECEDES | 1,697 | 1,709 | preserve | 1697-1699 | 1697-1699 | T118 | AG | OrganicChemical | 1,697 | 1,699 | preserve | 1673-1680 | 1673-1680 | T116 | therapy | TherapeuticOrPreventiveProcedure | 1,673 | 1,680 | A27 | Our study provides an insight as to why some patients fail therapy after extensive AG treatment. | 1608-1710 | 1,608 | 1,710 | Our study provides an insight as to why some patients fail @OBJECT$ after extensive @SUBJECT$ @PREDICAT$ . |
Fact | preserve | 121-123 | 121-123 | T10 | in | PROCESS_OF | 121 | 123 | preserve | 107-120 | 114-120 | T6 | breast cancer | NeoplasticProcess | 107 | 120 | preserve | 139-144 | 139-144 | T7 | women | PopulationGroup | 139 | 144 | A28 | Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women. | 0-145 | 0 | 145 | Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat @SUBJECT$ @PREDICAT$ postmenopausal @OBJECT$ . |
Fact | preserve | 876-888 | 879-888 | T92 | AG induction | USES | 876 | 888 | preserve | 879-888 | 879-888 | T72 | induction | TherapeuticOrPreventiveProcedure | 879 | 888 | preserve | 876-878 | 876-878 | T71 | AG | OrganicChemical | 876 | 878 | A29 | AG induction is thought to occur at the transcriptional level because the aromatase mRNA level elevated after AG treatment in SK-BR-3 and HepG2 cells, as demonstrated by reverse transcription-polymerase chain reaction (RT-PCR) analysis, and AG treatment did not increase aromatase activity in aromatase cDNA transfected cell lines (driven by the beta-actin promoter). | 876-1274 | 876 | 1,274 | @OBJECT$ @PREDICAT$ @SUBJECT$ is thought to occur at the transcriptional level because the aromatase mRNA level elevated after AG treatment in SK-BR-3 and HepG2 cells, as demonstrated by reverse transcription-polymerase chain reaction (RT-PCR) analysis, and AG treatment did not increase aromatase activity in aromatase cDNA transfected cell lines (driven by the beta-actin promoter). |
Fact | preserve | 1697-1709 | 1700-1709 | T120 | AG treatment | ISA | 1,697 | 1,709 | preserve | 1697-1699 | 1697-1699 | T118 | AG | OrganicChemical | 1,697 | 1,699 | preserve | 1700-1709 | 1700-1709 | T119 | treatment | TherapeuticOrPreventiveProcedure | 1,700 | 1,709 | A32 | Our study provides an insight as to why some patients fail therapy after extensive AG treatment. | 1608-1710 | 1,608 | 1,710 | Our study provides an insight as to why some patients fail therapy after extensive @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 146-174 | 170-174 | T22 | Aromatase, a cytochrome P450 | ISA | 146 | 174 | preserve | 146-155 | 146-155 | T11 | Aromatase | AminoAcidPeptideOrProtein | 146 | 155 | preserve | 159-174 | 170-174 | T12 | cytochrome P450 | AminoAcidPeptideOrProtein | 159 | 174 | A33 | Aromatase, a cytochrome P450, catalyzes three consecutive hydroxylation reactions converting C19 androgens to aromatic C18 estrogenic steroids. | 146-295 | 146 | 295 | @SUBJECT$ @PREDICAT$ @OBJECT$ , catalyzes three consecutive hydroxylation reactions converting C19 androgens to aromatic C18 estrogenic steroids. |
Fact | preserve | 697-709 | 700-709 | T58 | AG treatment | PRECEDES | 697 | 709 | preserve | 697-699 | 697-699 | T52 | AG | OrganicChemical | 697 | 699 | preserve | 673-680 | 673-680 | T50 | therapy | TherapeuticOrPreventiveProcedure | 673 | 680 | A34 | These results may explain why some patients failed therapy after extensive AG treatment. | 615-710 | 615 | 710 | These results may explain why some patients failed @OBJECT$ after extensive @SUBJECT$ @PREDICAT$ . |
Fact | preserve | 697-709 | 700-709 | T55 | AG treatment | USES | 697 | 709 | preserve | 700-709 | 700-709 | T53 | treatment | TherapeuticOrPreventiveProcedure | 700 | 709 | preserve | 697-699 | 697-699 | T52 | AG | OrganicChemical | 697 | 699 | A36 | These results may explain why some patients failed therapy after extensive AG treatment. | 615-710 | 615 | 710 | These results may explain why some patients failed therapy after extensive @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 2296-2371 | 2366-2371 | T151 | leukotriene receptor antagonists are very promising antiasthma drugs | ISA | 2,296 | 2,371 | preserve | 2296-2328 | 2317-2328 | T148 | leukotriene receptor antagonists | OrganicChemical | 2,296 | 2,328 | preserve | 2366-2371 | 2366-2371 | T150 | drugs | PharmacologicSubstance | 2,366 | 2,371 | A1 | In conclusion, the available results clearly indicate that leukotrienes play an important role in asthma and that cysteinyl leukotriene receptor antagonists are very promising antiasthma drugs. | 2160-2372 | 2,160 | 2,372 | In conclusion, the available results clearly indicate that leukotrienes play an important role in asthma and that cysteinyl @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1433-1435 | 1433-1435 | T98 | in | PROCESS_OF | 1,433 | 1,435 | preserve | 1413-1432 | 1413-1432 | T94 | bronchoconstriction | OrganOrTissueFunction | 1,413 | 1,432 | preserve | 1436-1442 | 1436-1442 | T95 | humans | Human | 1,436 | 1,442 | A2 | All the LTRAs are able to inhibit LTD4-induced bronchoconstriction in humans, albeit with different potencies. | 1360-1476 | 1,360 | 1,476 | All the LTRAs are able to inhibit LTD4-induced @SUBJECT$ @PREDICAT$ @OBJECT$ , albeit with different potencies. |
Fact | preserve | 64-177 | 83-86 | T27 | Leukotrienes (LTs) are among the most important mediators of asthma; cysteine-containing LTs (cysteinyl-LTs | ISA | 64 | 177 | preserve | 184-188 | 184-188 | T12 | LTC4 | BiologicallyActiveSubstance | 184 | 188 | preserve | 64-76 | 64-76 | T4 | Leukotrienes | BiologicallyActiveSubstance | 64 | 76 | A5 | Leukotrienes (LTs) are among the most important mediators of asthma; cysteine-containing LTs (cysteinyl-LTs, i.e. | 64-183 | 64 | 183 | @OBJECT$ @PREDICAT$ , i.e. @SUBJECT$ |
Fact | preserve | 1258-1280 | 1271-1280 | T88 | montelukast (Singulair | ISA | 1,258 | 1,280 | preserve | 1271-1280 | 1271-1280 | T81 | Singulair | OrganicChemical | 1,271 | 1,280 | preserve | 1258-1269 | 1258-1269 | T80 | montelukast | OrganicChemical | 1,258 | 1,269 | A6 | Among the many LTRAs, zafirlukast (Accolate, ICI 204,219), montelukast (Singulair, MK-476) and pranlukast (Onon, ONO-1078) are available for clinical use. | 1193-1359 | 1,193 | 1,359 | Among the many LTRAs, zafirlukast (Accolate, ICI 204,219), @OBJECT$ @PREDICAT$ @SUBJECT$ , MK-476) and pranlukast (Onon, ONO-1078) are available for clinical use. |
Fact | preserve | 64-177 | 83-86 | T27 | Leukotrienes (LTs) are among the most important mediators of asthma; cysteine-containing LTs (cysteinyl-LTs | ISA | 64 | 177 | preserve | 199-203 | 199-203 | T14 | LTE4 | BiologicallyActiveSubstance | 199 | 203 | preserve | 64-76 | 64-76 | T4 | Leukotrienes | BiologicallyActiveSubstance | 64 | 76 | A8 | Leukotrienes (LTs) are among the most important mediators of asthma; cysteine-containing LTs (cysteinyl-LTs, i.e. | 64-183 | 64 | 183 | @OBJECT$ @PREDICAT$ , i.e. @SUBJECT$ |
Fact | preserve | 2262-2266 | 2262-2266 | T152 | role | ASSOCIATED_WITH | 2,262 | 2,266 | preserve | 2225-2237 | 2225-2237 | T145 | leukotrienes | BiologicallyActiveSubstance | 2,225 | 2,237 | preserve | 2270-2276 | 2270-2276 | T147 | asthma | DiseaseOrSyndrome | 2,270 | 2,276 | A10 | In conclusion, the available results clearly indicate that leukotrienes play an important role in asthma and that cysteinyl leukotriene receptor antagonists are very promising antiasthma drugs. | 2160-2372 | 2,160 | 2,372 | In conclusion, the available results clearly indicate that @SUBJECT$ play an important @PREDICAT$ in @OBJECT$ and that cysteinyl leukotriene receptor antagonists are very promising antiasthma drugs. |
Fact | preserve | 64-177 | 83-86 | T27 | Leukotrienes (LTs) are among the most important mediators of asthma; cysteine-containing LTs (cysteinyl-LTs | ISA | 64 | 177 | preserve | 164-177 | 164-177 | T10 | cysteinyl-LTs | OrganicChemical | 164 | 177 | preserve | 64-76 | 64-76 | T4 | Leukotrienes | BiologicallyActiveSubstance | 64 | 76 | A11 | Leukotrienes (LTs) are among the most important mediators of asthma; cysteine-containing LTs (cysteinyl-LTs, i.e. | 64-183 | 64 | 183 | @OBJECT$ @PREDICAT$ @SUBJECT$ , i.e. |
Fact | preserve | 64-177 | 83-86 | T27 | Leukotrienes (LTs) are among the most important mediators of asthma; cysteine-containing LTs (cysteinyl-LTs | ISA | 64 | 177 | preserve | 190-194 | 190-194 | T13 | LTD4 | BiologicallyActiveSubstance | 190 | 194 | preserve | 64-76 | 64-76 | T4 | Leukotrienes | BiologicallyActiveSubstance | 64 | 76 | A12 | Leukotrienes (LTs) are among the most important mediators of asthma; cysteine-containing LTs (cysteinyl-LTs, i.e. | 64-183 | 64 | 183 | @OBJECT$ @PREDICAT$ , i.e. @SUBJECT$ |
Fact | preserve | 1875-1879 | 1875-1879 | T133 | with | PROCESS_OF | 1,875 | 1,879 | preserve | 1897-1903 | 1897-1903 | T125 | asthma | DiseaseOrSyndrome | 1,897 | 1,903 | preserve | 1866-1874 | 1866-1874 | T123 | patients | PatientOrDisabledGroup | 1,866 | 1,874 | A13 | Furthermore, although they are not bronchodilators per se, they increase basal forced expiratory volume in one second in patients with mild-to-moderate asthma, indicating that, in these individuals, constant cysteinyl-LT release contributes to maintaining increased bronchial tone. | 1739-2040 | 1,739 | 2,040 | Furthermore, although they are not bronchodilators per se, they increase basal forced expiratory volume in one second in @OBJECT$ @PREDICAT$ mild-to-moderate @SUBJECT$ , indicating that, in these individuals, constant cysteinyl-LT release contributes to maintaining increased bronchial tone. |
Fact | preserve | 495-529 | 524-529 | T42 | LTs are potential antiasthma drugs | ISA | 495 | 529 | preserve | 495-498 | 495-498 | T34 | LTs | BiologicallyActiveSubstance | 495 | 498 | preserve | 524-529 | 524-529 | T36 | drugs | PharmacologicSubstance | 524 | 529 | A14 | Therefore, compounds able to inhibit either the formation or the action of LTs are potential antiasthma drugs and, at present, the cysteinyl-LT receptor antagonists (LTRAs) appear to be the most promising. | 414-631 | 414 | 631 | Therefore, compounds able to inhibit either the formation or the action of @SUBJECT$ @PREDICAT$ @OBJECT$ and, at present, the cysteinyl-LT receptor antagonists (LTRAs) appear to be the most promising. |
Fact | preserve | 1162-1166 | 1162-1166 | T71 | with | PROCESS_OF | 1,162 | 1,166 | preserve | 1167-1169 | 1167-1169 | T65 | RA | DiseaseOrSyndrome | 1,167 | 1,169 | preserve | 1153-1161 | 1153-1161 | T64 | patients | PatientOrDisabledGroup | 1,153 | 1,161 | A1 | Estimates of the use of DMARD were based on the treatments reported on 502 visits by patients with RA in 1980-81, 339 visits by patients with RA in 1985, 386 visits by patients with RA in 1989-91, and 383 visits by patients with RA in 1993-95. | 972-1234 | 972 | 1,234 | Estimates of the use of DMARD were based on the treatments reported on 502 visits by patients with RA in 1980-81, 339 visits by patients with RA in 1985, 386 visits by @OBJECT$ @PREDICAT$ @SUBJECT$ in 1989-91, and 383 visits by patients with RA in 1993-95. |
Fact | preserve | 1215-1219 | 1215-1219 | T72 | with | PROCESS_OF | 1,215 | 1,219 | preserve | 1220-1222 | 1220-1222 | T68 | RA | DiseaseOrSyndrome | 1,220 | 1,222 | preserve | 1206-1214 | 1206-1214 | T67 | patients | PatientOrDisabledGroup | 1,206 | 1,214 | A2 | Estimates of the use of DMARD were based on the treatments reported on 502 visits by patients with RA in 1980-81, 339 visits by patients with RA in 1985, 386 visits by patients with RA in 1989-91, and 383 visits by patients with RA in 1993-95. | 972-1234 | 972 | 1,234 | Estimates of the use of DMARD were based on the treatments reported on 502 visits by patients with RA in 1980-81, 339 visits by patients with RA in 1985, 386 visits by patients with RA in 1989-91, and 383 visits by @OBJECT$ @PREDICAT$ @SUBJECT$ in 1993-95. |
Fact | preserve | 378-383 | 378-383 | T24 | treat | TREATS | 378 | 383 | preserve | 353-364 | 353-364 | T17 | medications | PharmacologicSubstance | 353 | 364 | preserve | 398-400 | 398-400 | T19 | RA | DiseaseOrSyndrome | 398 | 400 | A3 | We studied how often these medications were used to treat patients with RA, and whether use of these medications has increased over time. | 320-470 | 320 | 470 | We studied how often these @SUBJECT$ were used to @PREDICAT$ patients with @OBJECT$ , and whether use of these medications has increased over time. |
Fact | preserve | 1806-1808 | 1806-1808 | T112 | in | TREATS | 1,806 | 1,808 | preserve | 1800-1805 | 1800-1805 | T102 | DMARD | PharmacologicSubstance | 1,800 | 1,805 | preserve | 1809-1811 | 1809-1811 | T103 | RA | DiseaseOrSyndrome | 1,809 | 1,811 | A4 | CONCLUSION: Use of DMARD in RA has increased in the recent past, but DMARD are currently used by fewer than 44% of patients with RA. | 1775-1920 | 1,775 | 1,920 | CONCLUSION: Use of @SUBJECT$ @PREDICAT$ @OBJECT$ has increased in the recent past, but DMARD are currently used by fewer than 44% of patients with RA. |
Fact | preserve | 1122-1126 | 1122-1126 | T70 | with | PROCESS_OF | 1,122 | 1,126 | preserve | 1127-1129 | 1127-1129 | T62 | RA | DiseaseOrSyndrome | 1,127 | 1,129 | preserve | 1113-1121 | 1113-1121 | T61 | patients | PatientOrDisabledGroup | 1,113 | 1,121 | A5 | Estimates of the use of DMARD were based on the treatments reported on 502 visits by patients with RA in 1980-81, 339 visits by patients with RA in 1985, 386 visits by patients with RA in 1989-91, and 383 visits by patients with RA in 1993-95. | 972-1234 | 972 | 1,234 | Estimates of the use of DMARD were based on the treatments reported on 502 visits by patients with RA in 1980-81, 339 visits by @OBJECT$ @PREDICAT$ @SUBJECT$ in 1985, 386 visits by patients with RA in 1989-91, and 383 visits by patients with RA in 1993-95. |
Fact | preserve | 1072-1076 | 1072-1076 | T69 | with | PROCESS_OF | 1,072 | 1,076 | preserve | 1077-1079 | 1077-1079 | T58 | RA | DiseaseOrSyndrome | 1,077 | 1,079 | preserve | 1063-1071 | 1063-1071 | T57 | patients | PatientOrDisabledGroup | 1,063 | 1,071 | A6 | Estimates of the use of DMARD were based on the treatments reported on 502 visits by patients with RA in 1980-81, 339 visits by patients with RA in 1985, 386 visits by patients with RA in 1989-91, and 383 visits by patients with RA in 1993-95. | 972-1234 | 972 | 1,234 | Estimates of the use of DMARD were based on the treatments reported on 502 visits by @OBJECT$ @PREDICAT$ @SUBJECT$ in 1980-81, 339 visits by patients with RA in 1985, 386 visits by patients with RA in 1989-91, and 383 visits by patients with RA in 1993-95. |
Fact | preserve | 378-383 | 378-383 | T24 | treat | TREATS | 378 | 383 | preserve | 353-364 | 353-364 | T17 | medications | PharmacologicSubstance | 353 | 364 | preserve | 384-392 | 384-392 | T18 | patients | PatientOrDisabledGroup | 384 | 392 | A7 | We studied how often these medications were used to treat patients with RA, and whether use of these medications has increased over time. | 320-470 | 320 | 470 | We studied how often these @SUBJECT$ were used to @PREDICAT$ @OBJECT$ with RA, and whether use of these medications has increased over time. |
Fact | preserve | 1912-1916 | 1912-1916 | T113 | with | PROCESS_OF | 1,912 | 1,916 | preserve | 1917-1919 | 1917-1919 | T110 | RA | DiseaseOrSyndrome | 1,917 | 1,919 | preserve | 1903-1911 | 1903-1911 | T109 | patients | PatientOrDisabledGroup | 1,903 | 1,911 | A8 | CONCLUSION: Use of DMARD in RA has increased in the recent past, but DMARD are currently used by fewer than 44% of patients with RA. | 1775-1920 | 1,775 | 1,920 | CONCLUSION: Use of DMARD in RA has increased in the recent past, but DMARD are currently used by fewer than 44% of @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 393-397 | 393-397 | T25 | with | PROCESS_OF | 393 | 397 | preserve | 398-400 | 398-400 | T19 | RA | DiseaseOrSyndrome | 398 | 400 | preserve | 384-392 | 384-392 | T18 | patients | PatientOrDisabledGroup | 384 | 392 | A10 | We studied how often these medications were used to treat patients with RA, and whether use of these medications has increased over time. | 320-470 | 320 | 470 | We studied how often these medications were used to treat @OBJECT$ @PREDICAT$ @SUBJECT$ , and whether use of these medications has increased over time. |
Fact | preserve | 769-773 | 769-773 | T45 | with | PROCESS_OF | 769 | 773 | preserve | 774-776 | 774-776 | T44 | RA | DiseaseOrSyndrome | 774 | 776 | preserve | 760-768 | 760-768 | T43 | patients | PatientOrDisabledGroup | 760 | 768 | A12 | METHODS: We used the National Ambulatory Medical Care Surveys to determine national probability estimates of the use of DMARD [hydroxychloroquine, intramuscular gold, auranofin, methotrexate (MTX), sulfasalazine, azathioprine, D-penicillamine, and cyclosporine] by patients with RA. | 471-777 | 471 | 777 | METHODS: We used the National Ambulatory Medical Care Surveys to determine national probability estimates of the use of DMARD [hydroxychloroquine, intramuscular gold, auranofin, methotrexate (MTX), sulfasalazine, azathioprine, D-penicillamine, and cyclosporine] by @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 2117-2120 | 2117-2120 | T148 | had | PROCESS_OF | 2,117 | 2,120 | preserve | 2160-2166 | 2160-2166 | T138 | reflux | PathologicFunction | 2,160 | 2,166 | preserve | 2076-2084 | 2076-2084 | T131 | Children | AgeGroup | 2,076 | 2,084 | A1 | CONCLUSIONS: Children with DGE, who did not have GEP, had twice the frequency of recurrent reflux as those who had a GER Preoperative screening for DGE, as well as operative correction of DGE at the time of fundoplication, is therefore recommended. | 2057-2329 | 2,057 | 2,329 | CONCLUSIONS: @OBJECT$ with DGE, who did not have GEP, @PREDICAT$ twice the frequency of recurrent @SUBJECT$ as those who had a GER Preoperative screening for DGE, as well as operative correction of DGE at the time of fundoplication, is therefore recommended. |
Fact | preserve | 2213-2216 | 2213-2216 | T149 | for | TREATS | 2,213 | 2,216 | preserve | 2203-2212 | 2203-2212 | T141 | screening | HealthCareActivity | 2,203 | 2,212 | preserve | 2217-2220 | 2217-2220 | T142 | DGE | Finding | 2,217 | 2,220 | A3 | CONCLUSIONS: Children with DGE, who did not have GEP, had twice the frequency of recurrent reflux as those who had a GER Preoperative screening for DGE, as well as operative correction of DGE at the time of fundoplication, is therefore recommended. | 2057-2329 | 2,057 | 2,329 | CONCLUSIONS: Children with DGE, who did not have GEP, had twice the frequency of recurrent reflux as those who had a GER Preoperative @SUBJECT$ @PREDICAT$ @OBJECT$ , as well as operative correction of DGE at the time of fundoplication, is therefore recommended. |
Fact | preserve | 86-88 | 86-88 | T8 | in | PROCESS_OF | 86 | 88 | preserve | 73-79 | 73-79 | T5 | reflux | PathologicFunction | 73 | 79 | preserve | 89-97 | 89-97 | T6 | children | AgeGroup | 89 | 97 | A5 | Gastric emptying procedures decrease the risk of postoperative recurrent reflux in children with delayed gastric emptying. | 0-128 | 0 | 128 | Gastric emptying procedures decrease the risk of postoperative recurrent @SUBJECT$ @PREDICAT$ @OBJECT$ with delayed gastric emptying. |
Fact | preserve | 1064-1068 | 1064-1068 | T69 | with | PROCESS_OF | 1,064 | 1,068 | preserve | 1069-1072 | 1069-1072 | T65 | DGE | Finding | 1,069 | 1,072 | preserve | 1055-1063 | 1055-1063 | T64 | patients | PatientOrDisabledGroup | 1,055 | 1,063 | A6 | RESULTS: Of the 183 patients with DGE, 92 were available for long-term follow-up. | 1029-1116 | 1,029 | 1,116 | RESULTS: Of the 183 @OBJECT$ @PREDICAT$ @SUBJECT$ , 92 were available for long-term follow-up. |
Fact | preserve | 715-718 | 715-718 | T51 | had | PROCESS_OF | 715 | 718 | preserve | 721-743 | 734-743 | T46 | preoperative diagnosis | Finding | 721 | 743 | preserve | 630-638 | 630-638 | T42 | children | AgeGroup | 630 | 638 | A7 | METHODS: A retrospective chart review was performed on all children under the age of 16 years, operated on for GER from 1980 to 1997, who had a preoperative diagnosis of DGE, and at least 6 months of follow-up. | 565-787 | 565 | 787 | METHODS: A retrospective chart review was performed on all @OBJECT$ under the age of 16 years, operated on for GER from 1980 to 1997, who @PREDICAT$ a @SUBJECT$ of DGE, and at least 6 months of follow-up. |
Fact | preserve | 98-102 | 98-102 | T9 | with | PROCESS_OF | 98 | 102 | preserve | 103-127 | 119-127 | T7 | delayed gastric emptying | Finding | 103 | 127 | preserve | 89-97 | 89-97 | T6 | children | AgeGroup | 89 | 97 | A8 | Gastric emptying procedures decrease the risk of postoperative recurrent reflux in children with delayed gastric emptying. | 0-128 | 0 | 128 | Gastric emptying procedures decrease the risk of postoperative recurrent reflux in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 955-964 | 955-964 | T62 | confirmed | DIAGNOSES | 955 | 964 | preserve | 988-998 | 988-998 | T60 | esophagram | DiagnosticProcedure | 988 | 998 | preserve | 941-953 | 945-953 | T59 | GER symptoms | SignOrSymptom | 941 | 953 | A9 | Recurrent reflux was defined as reappearance of GER symptoms, confirmed by postoperative esophagram or 24 hours of pH monitoring. | 893-1028 | 893 | 1,028 | Recurrent reflux was defined as reappearance of @OBJECT$ , @PREDICAT$ by postoperative @SUBJECT$ or 24 hours of pH monitoring. |
Fact | preserve | 2085-2089 | 2085-2089 | T147 | with | PROCESS_OF | 2,085 | 2,089 | preserve | 2090-2093 | 2090-2093 | T132 | DGE | Finding | 2,090 | 2,093 | preserve | 2076-2084 | 2076-2084 | T131 | Children | AgeGroup | 2,076 | 2,084 | A11 | CONCLUSIONS: Children with DGE, who did not have GEP, had twice the frequency of recurrent reflux as those who had a GER Preoperative screening for DGE, as well as operative correction of DGE at the time of fundoplication, is therefore recommended. | 2057-2329 | 2,057 | 2,329 | CONCLUSIONS: @OBJECT$ @PREDICAT$ @SUBJECT$ , who did not have GEP, had twice the frequency of recurrent reflux as those who had a GER Preoperative screening for DGE, as well as operative correction of DGE at the time of fundoplication, is therefore recommended. |